Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary

Liu, Catherine; Bayer, Arnold S.; Cosgrove, Sara E.; Daum, Robert S.; Fridkin, Scott K.; Gorwitz, Rachel J.; Kaplan, Sheldon L.; Karchmer, Adolf W.; Levine, Donald P.; Murray, Barbara E.; Rybak, Michael J.; Talan, David A.; Chambers, Henry F.

doi:10.1093/cid/cir034

Cited by 1,443 publications

(1,245 citation statements)

References 25 publications

Supporting

Mentioning

1,184

Contrasting

Unclassified

Order By: Relevance

“…The rate of adequate echocardiography was calculated as the number of patients with echocardiography / the number of patients with complicated bacteremia. Uncomplicated bacteremia was defined according to the Clinical Practice Guidelines of the Infectious Disease Society of America for the treatment of MRSA infections 1. We regarded the cases as uncomplicated bacteremia if they met all of the following criteria: exclusion of endocarditis, absence of implanted prostheses, negative follow‐up blood cultures, defervescence within 72 h of therapy, and absence of evidence of metastatic sites of infection.…”

Section: Methodsmentioning

confidence: 99%

“…Staphylococcus aureus bacteremia (SAB) causes significant morbidity and mortality, and usually causes complications (e.g., infective endocarditis and metastatic abscess). For the prevention and early detection of these complications, US guidelines for methicillin‐resistant S. aureus (MRSA) infection recommended several specific management strategies, particularly follow‐up blood cultures, sufficient treatment duration, and echocardiography 1. Several observational studies have reported that a higher rate of adherence to these recommendations was associated with lower SAB‐related mortality 2, 3…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Adherence rate of quality‐of‐care indicators for Staphylococcus aureus bacteremia is extremely low in Japanese emergency and critical care departments: a multicenter retrospective observational study

Miyamoto

Kato

Kitayama

et al. 2017

Acute Medicine & Surgery

View full text Add to dashboard Cite

Aim Staphylococcus aureus bacteremia causes significant morbidity and mortality and requires specific management to prevent complications. Most studies evaluating quality of care have been carried out in Europe and North America, and accurate epidemiological data are lacking in Asia. We aimed to describe the epidemiology and evaluate the quality of care for S. aureus bacteremia in Japan.MethodsFrom February 2011 to January 2014, we undertook a multicenter retrospective observational study in 10 departments of emergency and critical care in Japan. We included 118 hospitalized adult patients with S. aureus bacteremia and evaluated three quality‐of‐care indicators: follow‐up blood culture, treatment duration, and echocardiography.ResultsThe mean age of the patients was 63.5 ± 17.0 years. The major source of bacteremia was pneumonia (n = 22, 19%), followed by skin and soft tissue infection (n = 18, 15%). Thirty patients (25%) died in the hospital. Follow‐up blood culture was performed in 21/112 patients (19%). The duration of antimicrobial treatment was sufficient in 49/87 patients (56%). Echocardiography for patients with clinical indication was undertaken in 39/59 patients (66%). Any of the three indicators were inadequate in 101/118 (86%).ConclusionThe rate of adequate care for S. aureus bacteremia is low in Japan. The low adherence rate for follow‐up blood culture was particularly notable. Staphylococcus aureus bacteremia can be an important target of quality improvement interventions.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Adherence rate of quality‐of‐care indicators for Staphylococcus aureus bacteremia is extremely low in Japanese emergency and critical care departments: a multicenter retrospective observational study

Miyamoto

Kato

Kitayama

et al. 2017

Acute Medicine & Surgery

View full text Add to dashboard Cite

show abstract

“…In patients with CF infected with MRSA who are experiencing an acute pulmonary exacerbation, vancomycin and linezolid are the first-line antimicrobial choices (34,35). Dosing of vancomycin is based on the patient's weight and creatinine clearance.…”

Section: Methicillin-resistant Staphylococcus Aureusmentioning

confidence: 99%

Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections

et al. 2014

View full text Add to dashboard Cite

Despite significant advances in treatment strategies targeting the underlying defect in cystic fibrosis (CF), airway infection remains an important cause of lung disease. In this two-part series, we review recent evidence related to the complexity of CF airway infection, explore data suggesting the relevance of individual microbial species, and discuss current and future treatment options. In Part I, the evidence with respect to the spectrum of bacteria present in the CF airway, known as the lung microbiome is discussed. Subsequently, the current approach to treat methicillin-resistant Staphylococcus aureus, gram-negative bacteria, as well as multiple coinfections is reviewed. Newer molecular techniques have demonstrated that the airway microbiome consists of a large number of microbes, and the balance between microbes, rather than the mere presence of a single species, may be relevant for disease pathophysiology. A better understanding of this complex environment could help define optimal treatment regimens that target pathogens without affecting others. Although relevance of these organisms is unclear, the pathologic consequences of methicillin-resistant S. aureus infection in patients with CF have been recently determined. New strategies for eradication and treatment of both acute and chronic infections are discussed. Pseudomonas aeruginosa plays a prominent role in CF lung disease, but many other nonfermenting gram-negative bacteria are also found in the CF airway. Many new inhaled antibiotics specifically targeting P. aeruginosa have become available with the hope that they will improve the quality of life for patients. Part I concludes with a discussion of how best to treat patients with multiple coinfections.

show abstract

“…The most recent guidelines on the treatment of MRSA published by the Infectious Diseases Society of America (IDSA) in 2011 give no information on the importance of an MIC within the susceptible range for clinical decision-making [10,11]. However, these were written in 2010 and evidence has continued to emerge since their inception and subsequent publication.…”

Section: The Vancomycin Breakpointmentioning

confidence: 99%

Treatment options for methicillin-resistant Staphylococcus aureus (MRSA) infection: Where are we now?

Edwards

Andini

Esposito

et al. 2014

Journal of Global Antimicrobial Resistance

View full text Add to dashboard Cite

Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children: Executive Summary

Cited by 1,443 publications

References 25 publications

Adherence rate of quality‐of‐care indicators for Staphylococcus aureus bacteremia is extremely low in Japanese emergency and critical care departments: a multicenter retrospective observational study

Adherence rate of quality‐of‐care indicators for Staphylococcus aureus bacteremia is extremely low in Japanese emergency and critical care departments: a multicenter retrospective observational study

Antibiotic Management of Lung Infections in Cystic Fibrosis. I. The Microbiome, Methicillin-Resistant Staphylococcus aureus, Gram-Negative Bacteria, and Multiple Infections

Treatment options for methicillin-resistant Staphylococcus aureus (MRSA) infection: Where are we now?

Contact Info

Product

Resources

About